NCT00038909已完成不适用
Factor VIII Mutation Testing Program in Previously Untreated Patients (PUPs) With Hemophilia A Participating in ReFacto® Study
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 103 人开始时间: 1994年9月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 103
研究概览
简要总结
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto® clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using two established hemophilia mutation testing laboratories (one in Europe and one in North America).
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been treated with ReFacto® during this study are eligible for participation.
- •The patient (or legal guardian) must be willing to give written informed consent before any study-related procedures are performed.
- •A blood sample will be collected from each patient for the purpose of this study and will be analyzed at one or both of the designated central laboratories.
排除标准
- •Any condition which, in the investigator's opinion, places the patient at undue risk.
研究者
相似试验
招募中
不适用
Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia AHemophilia A, MildDesmopressinFactor VIIINCT05628558Groupe Maladies hémorragiques de Bretagne800
已完成
不适用
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in HemophiliaHemophilia ANCT00178607The University of Texas Health Science Center, Houston99
已完成
不适用
Genetic Factors of the Desmopressin Response in Carriers of Hemophilia ACarrier of Hemophilia ADesmopressinFactor VIII DeficiencyNCT06020456Groupe Maladies hémorragiques de Bretagne361
Unknown
不适用
Personalized Prediction of Tolerance and Immunogenicity in HemophiliaHemophilia ANCT01626105Victor J Marder, M.D.55
已完成
不适用
Platelet Function in Patients With Hemophilia AHemophilia ANCT02093065Boston Children's Hospital36